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Abstract
Background:  Biochemical testing for pheochromocytoma by measurement of fractionated plasma
metanephrines is limited by false positive rates of up to 18% in people without known genetic
predisposition to the disease. The plasma normetanephrine fraction is responsible for most false positives
and plasma normetanephrine increases with age. The objective of this study was to determine if we could
improve the specificity of fractionated plasma measurements, by statistically adjusting for age.
Methods: An age-adjusted metanephrine score was derived using logistic regression from 343 subjects
(including 33 people with pheochromocytoma) who underwent fractionated plasma metanephrine
measurements as part of investigations for suspected pheochromocytoma at Mayo Clinic Rochester
(derivation set). The performance of the age-adjusted score was validated in a dataset of 158 subjects
(including patients 23 with pheochromocytoma) that underwent measurements of fractionated plasma
metanephrines at Mayo Clinic the following year (validation dataset). None of the participants in the
validation dataset had known genetic predisposition to pheochromocytoma.
Results: The sensitivity of the age-adjusted metanephrine score was the same as that of traditional
interpretation of fractionated plasma metanephrine measurements, yielding a sensitivity of 100% (23/23,
95% confidence interval [CI] 85.7%, 100%). However, the false positive rate with traditional interpretation
of fractionated plasma metanephrine measurements was 16.3% (22/135, 95% CI, 11.0%, 23.4%) and that
of the age-adjusted score was significantly lower at 3.0% (4/135, 95% CI, 1.2%, 7.4%) (p < 0.001 using
McNemar's test).
Conclusion: An adjustment for age in the interpretation of results of fractionated plasma metanephrines
may significantly decrease false positives when using this test to exclude sporadic pheochromocytoma.
Such improvements in false positive rate may result in savings of expenditures related to confirmatory
imaging.
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Background
Pheochromocytoma is a rare tumor of the adrenal
medulla or sympathetic ganglia, which can secrete exces-
sive catecholamines [1]. Signs and symptoms of pheo-
chromocytoma may include hypertension, pain
(including headache, flank pain, abdominal pain, or chest
pain), hyperhidrosis, anxiety or panic attacks, cardiac
arrythmias, or sudden death [1-6]. A pheochromocytoma
may also be detected as an asymptomatic incidental adre-
nal mass seen on abdominal imaging [7]. Metabolites of
norepinephrine and epinephrine, specifically normetane-
phrine and metanephrine, may be measured in the
plasma by high performance liquid chromatography with
electrochemical detection, as described by Lenders et al.
[8]. Measurement of fractionated plasma metanephrines
has been called "the best test for excluding or confirming
pheochromocytoma" and some investigators have recom-
mended that such measurements "should be the test of
first choice" [9]. In a recent systematic review of the world
literature, we have observed that measurement of fraction-
ated plasma metanephrine measurements have a high
sensitivity ranging of 96 to100% and a variable specificity
ranging from 82% to 100% [10]. The specificity of frac-
tionated plasma metanephrines in excluding pheochro-
mocytoma appears lowest in populations without known
genetic predisposition to disease (those in whom sporadic
disease is sought), with a false positive rate of up to 18%
in such patients [9]. We have previously observed that the
normetanephrine fraction is elevated in the majority of
false positive test results and that false positives are asso-
ciated with increasing age [11]. Indeed, investigators from
the National Institute of Health have agreed that, "meas-
urements of plasma normetanephrine and metanephrine
provide a highly sensitive test for diagnosis of pheochro-
mocytoma, but false positive results remain a problem"
[12]. False positive biochemical test results may result in
needless imaging procedures and generate excessive
healthcare expenditures in detection of sporadic pheo-
chromocytoma [13].
Reasons for false positive fractionated metanephrine test
results have been explored and alternatives for further
evaluation of patients with positive test results have been
proposed. It is known that acetaminophen may interfere
with measurements of fractionated plasma metane-
phrines using the Lenders' method [8], so this drug has
traditionally been avoided prior to testing. Eisenhofer and
colleagues have also suggested that that tricyclic antide-
pressants and phenoxybenzamine, respectively, may
result in false positive tests [12]. Of note, in a recent Mayo
study, 13% of subjects with false positive fractionated
metanephrines used tricyclic antidepressants [11] but 9%
of subjects who had normal fractionated metanephrine
measurements also used these drugs. Thus, tricyclic use
did not seem to explain the majority of false positives seen
at the Mayo Clinic. Furthermore, given that phenoxyben-
zamine is rarely used in patients without known pheo-
chromocytoma, use of this drug does not explain why
there are so many false positive fractionated metane-
phrine results observed in clinical practice. As a method to
distinguish false positives from true positives, Eisenhofer
and colleagues have recommended clonidine-suppression
testing in patients with positive fractionated plasma
metanephrine measurements [12]. Eisenhofer and col-
leagues have recommended that plasma norepinephrine
and normetanephrine levels be measured three hours
after a dose of 0.3 mg clonidine in such patients [12]. We
have proposed an alternative strategy to deal with false
positive test results in patients without known genetic pre-
disposition to disease [13]. As normetanephrine is the
fraction responsible for the majority of false positive
results, we have proposed that 24-hour urinary measure-
ments of fractionated catecholamines and metanephrines
be performed in patients with normetanephrine eleva-
tions that are approximately one and two times the upper
limit of the normal range, to confirm the biochemical
presence of sporadic pheochromocytoma [13]. Of note, in
the case of high risk patients with known genetic predis-
position to pheochromocytoma, the pre-test probability
of disease may be sufficiently high that measurement of
fractionated plasma metanephrines, without confirma-
tory biochemical studies may be reasonable [11]. Thus,
the issue of lack of specificity of fractionated plasma
metanephrine measurements is applicable primarily to
non-genetically predisposed individuals in whom spo-
radic pheochromocytoma is sought.
Our objective was to determine whether an adjustment of
fractionated plasma metanephrines for age may improve
the specificity of interpretation of these measurements
when biochemically excluding sporadic pheochromocy-




The age-adjusted fractionated plasma metanephrine score
was derived from a previously described dataset of 349
subjects (including 33 people with pheochromocytoma)
who underwent measurement of fractionated plasma
metanephrines as part of an evaluation of suspected phe-
ochromocytoma (also known as the derivation set) [11].
The diagnostic efficacy of this logistic-regression derived
prediction rule was then tested in a second dataset of 158
subjects (including 23 with sporadic pheochromocy-
toma) who had measurements of fractionated plasma
metanephrines performed at the Mayo Clinic Rochester
the following year (the validation dataset). None of the
patients in the validation set had known genetic predispo-
sition to pheochromocytoma. All patients withBMC Endocrine Disorders 2005, 5:1 http://www.biomedcentral.com/1472-6823/5/1
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pheochromocytoma had histologic confirmation of the
diagnosis and those without pheochromocytoma had an
alternative diagnosis assigned at the completion of their
evaluation based on a combination of other biochemical
test results (such as normal 24-hour urinary fractionated
metanephrine and catecholamine measurements with or
without normal imaging of the adrenals in the form of
computerized tomography scanning [CT] or magnetic res-
onance imaging [MRI]). All data were obtained by retro-
spective chart review. The Institutional Review Board at
Mayo Clinic Rochester approved the study.
Measurement of fractionated plasma metanephrines
The technique of Lenders (by high performance chroma-
tography and electrochemical detection) was used to
measure fractionated plasma metanephrines [8]. The tra-
ditional criterion for positivity is a metanephrine fraction
greater than or equal to 0.5 nmol/L or a normetanephrine
fraction greater than or equal to 0.9 nmol/L, based on a
95% reference range derived by Mayo Medical Laborato-
ries. Subjects were advised to avoid acetaminophen for 48
hours prior to measurement of fractionated plasma
metanephrines. Fractionated plasma metanephrine meas-
urements were taken in the sitting position, with no ind-
welling venous cannula, and no dietary restrictions prior
to testing. The lower limit of detection for the normetane-
phrine and metanephrine fractions was 0.20 nmol/L.
Therefore, normetanephrine and metanephrine fractional
measurements reported as being below the detection limit
were given the value of 0.19 nmol/L for use in the logistic
regression formula. Subjects who had "interfering sub-
stances" reported by the laboratory on measurement of
fractionated plasma metanephrines were excluded from
analyses but the number of such subjects was recorded.
Statistical methods
Clinical characteristics of subjects in the derivation set
who did not have pheochromocytoma but had measure-
ments of the normetanephrine or metanephrine fraction
above the upper reference limits (false positive tests using
traditional positivity criteria) were compared to those
without pheochromocytoma who had true negative tests
(χ2 was used for categorical variables and Student's t-test
for independent samples was used for continuous varia-
bles). Variables which were different between both groups
at a significance level of 0.1 were then entered into a mul-
tivariable logistic regression model predicting pheochro-
mocytoma. Age was the only variable of statistical
significance distinguishing true positive from false posi-
tive fractionated plasma metanephrine measurements in
the derivation set. Thus, we forced age with measurement
values of normetanephrine and metanephrine fractions in
a multivariable logistic regression model predicting pheo-
chromocytoma in the derivation set (SPSS 10.0, Chicago,
ILL). The formula for this age-adjusted fractionated
plasma metanephrine score is shown below:
-4.188 + -0.07(age) + 4.516(metanephrine) +
3.129(normetanephrine).
Age was in years, metanephrine fraction in nmol/L and
normetanephrine fraction in nmol/L in this formula. In
the derivation set, the Hosmer and Lemeshow test had χ2
= 4.73, df = 8, p = 0.79 and the Cox and Snell r2 = 0.38
showing significant model goodness-of-fit. A positivity
cut-off age-adjusted metanephrine value of = -1.4752 was
chosen as it carried an acceptable sensitivity of = 90.9%
(30/33 patients, 95% CI = 76.4%, 96.9%) and specificity
of 96.8% (300/310 patients, 95% CI = 94.2%, 98.2%) in
the derivation set. The sensitivity level of over 90% was
chosen because such a sensitivity level was believed to be
clinically reasonable and at this level, specificity was still
acceptable. We were aware that the lower the cut-off, the
higher the sensitivity, but this would be at the expense of
specificity.
The formula for adjustment of age was applied to fraction-
ated plasma metanephrine measurements in the second
dataset (validation dataset) for testing of sensitivity and
specificity in a population in whom sporadic pheochro-
mocytoma was sought. In the validation set, individuals
with known genetic predisposition to pheochromocy-
toma were excluded. Sensitivities were calculated by divi-
sion of subjects with true positive test results by all the
subjects with pheochromocytoma, and specificities were
calculated by division of subjects with true negative test
results divided by all subjects without pheochromocy-
toma. For sensitivities, specificities, and likelihood ratios,
95 percent confidence intervals (CI) were calculated using
Wilson's method (except the Score Method was used for
calculation of 95% CI of likelihood ratios when a zero cell
was noted) [14]. The specificity of the age-adjusted
metanephrine score were compared (at the same level of
sensitivity) to traditional interpretation of fractionated
plasma metanephrine measurements using McNemar's
test [15].
Economic evaluation (decision analysis)
We investigated whether use of an age-adjusted fraction-
ated plasma metanephrine measurement could result in
cost savings in imaging expenditures, compared to use of
fractionated plasma metanephrine measurements inter-
preted in a conventional fashion, for detection of sporadic
pheochromocytoma in a hypothetical tertiary care hyper-
tensive population. We thus performed a decision analy-
sis, with resource implications defined by costs of
confirmatory imaging (CT and MRI), interpreted from a
third party payer perspective. In the decision analysis, we
compared algorithm "A" in which biochemical testingBMC Endocrine Disorders 2005, 5:1 http://www.biomedcentral.com/1472-6823/5/1
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consisted of measurement of fractionated plasma metane-
phrines with these measurements interpreted relative to
the 95% reference range (defined by a normetanephrine
fraction above 0.9 nmol/L or a metanephrine fraction
above 0.5 nmol/L) to algorithm "B", in which fraction-
ated plasma metanephrine measurements were inter-
preted by using the age-adjusted metanephrine score. The
sensitivity and specificity of biochemical tests was based
on data from the validation set. In each algorithm, all
patients with positive biochemical testing would undergo
confirmatory imaging. The imaging protocol for patients
with positive biochemical tests in either strategies began
with computerized tomography ([CT] with and without
intravenous contrast) of the abdomen, then if negative, I-
131 or I-123 metaiodobenzylguanidine (MIBG) scintigra-
phy (efficacy for I-131 and costs for I-123 shown). The
horizon (endpoint) of the analyses was positive diagnosis
or exclusion of pheochromocytoma, for hypothetical
hypertensive patients subjected to each strategy. The out-
come of the analyses was the number of patients with
pheochromocytoma expected to be detected by each strat-
egy. The costs of false positive biochemical tests were
reflected only in the costs of subsequent imaging and not
in potential costs of needless surgery or its possible
complications.
The diagnostic efficacy of imaging studies was based on
respective estimates from the literature: The sensitivity of
CT imaging of the abdomen was assumed to be 98% with
a specificity of 70% [16]. The sensitivity of MIBG in
detecting benign sporadic pheochromocytoma was
assumed to be 87.4% with a specificity of 98.9% [17].
All costs were reported in 2002 US dollars. Costs of imag-
ing investigations were obtained from the Mayo Clinic
Rochester Business Office. For the purpose of the decision
analysis model, the prevalence of pheochromocytoma in
the hypertensive population that would typically be
screened was assumed to be 0.5% [18].
Results
Findings in the derivation set
The derivation set (from which the age-adjusted score was
developed) consisted of 349 consecutive subjects (includ-
ing 33 people with pheochromocytoma) who underwent
fractionated plasma metanephrine measurements as well
as 24-hour urinary total metanephrine measurements
with or without 24-hour urinary catecholamine measure-
ments in testing for pheochromocytoma at Mayo Clinic
Rochester. In the derivation set, 8 of the 33 individuals
had clinically-diagnosed genetic syndromes predisposing
to pheochromocytoma (three familial malignant para-
ganglioma, two von Hippel-Lindau, one had multiple
endocrine neoplasia 2a, one had multiple endocrine neo-
plasia 2b, and one had familial multiple benign paragan-
glioma). The 316 individuals in the derivation set who did
not have pheochromocytoma underwent such testing the
following reasons: refractory hypertension (174, 55%),
spells (periodic episodes of symptoms such as palpita-
tions, headache, or sweating, 124, 39%), adrenal mass
(45, 14%), previous pheochromocytoma or known
genetic predisposition to pheochromocytoma (24, 8%).
The mean age of subjects with pheochromocytoma was 48
years (SD 18 years, range 16 to 60 years), whereas the
mean age of subjects without pheochromocytoma was 52
years (SD 15 years, range 10 to 73 years). Six of the 316
subjects without pheochromocytoma in the derivation set
did not have a plasma metanephrine fraction recorded
secondary to "interfering substances" and therefore were
excluded from the analyses. In the derivation set, the sen-
sitivity of traditionally interpreted fractionated plasma
metanephrine measurements (using 95% reference
ranges) was 93.9% (95% CI, 80.4, 98.3) (31/33 subjects),
with a specificity of 85.2% (95% CI, 80.8, 88.7) (264/310
subjects). Baseline characteristics of individuals in the der-
ivation set without pheochromocytoma were compared
for individuals who had true negative fractionated
metanephrine measurements (n = 264) to those who had
false positive results (n = 46) (Table 1). The individuals
with false positive fractionated plasma metanephrine
measurements in the derivation set were significantly
older than those with true negative measurements (p =
0.007), whereas blood pressure, antihypertensive medica-
tion use, and rates of obstructive sleep apnea were not sig-
nificantly different between these groups. Thus, age was
chosen as an important variable to adjust for in interpre-
tation of fractionated plasma metanephrines and an age-
adjusted metanephrine score was developed from the der-
ivation set data using logistic regression (as described in
the Methods). At a cut-off value of -1.4752, the sensitivity
of the age-adjusted metanephrine score was 90.9% (30/33
patients, 95% CI, 76.4%, 96.9%), with a specificity of
96.8% (300/310 patients, 95% CI, 94.2%, 98.2%). In this
derivation set, which included individuals genetically pre-
disposed to pheochromocytoma, one individual with a
dopamine-secreting paraganglioma, another patient with
a von Hippel-Lindau disease (diagnosed clinically), and a
third patient with sporadic pheochromocytoma had false-
negative age-adjusted metanephrine scores. The efficacy of
the age-adjusted metanephrine score was then validated
in the validation set.
Findings in the validation set
In the validation set of 158 subjects, 23 patients had his-
tologically-proven sporadic pheochromocytoma (17
adrenal, 6 extra-adrenal, 8 malignant). Of the patients
with pheochromocytoma, none were known to be genet-
ically predisposed to pheochromocytoma and 14/23 were
women (61%). The mean age of subjects with pheochro-
mocytoma was 50 years (SD 16 years, range 16 to 83BMC Endocrine Disorders 2005, 5:1 http://www.biomedcentral.com/1472-6823/5/1
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years), whereas the mean age of subjects without pheo-
chromocytoma was 55 years (SD 16 years, range 7 to 86
years). Of the 135 subjects without pheochromocytoma,
83 (62%) were women. Reasons for measurement of frac-
tionated plasma metanephrines in the subjects without
pheochromocytoma were as follows: hypertension (55,
41%), spells with or without hypertension (44, 33%), an
incidentally discovered adrenal mass (20, 15%), and pre-
viously surgically cured pheochromocytoma (16, 12%).
In the validation set, the sensitivity of the age-adjusted
metanephrine score was the same as the traditional inter-
pretation of fractionated plasma metanephrine measure-
ments at 100% (23/23, 95% CI, 85.7%, 100%). The
specificity of the traditional interpretation of fractionated
plasma metanephrine measurements was 83.7% (113/
135 patients, 95% CI, 76.6%, 89.0%) and the specificity
of the age-adjusted plasma metanephrine score was
97.0% (131/135 patients, 95% CI, 92.6%, 98.8%). Thus,
the false positive rate with traditional interpretation of
fractionated plasma metanephrine measurements was
16.3% (22/135, 95% CI, 11.0%, 23.4%) and with the age-
adjusted score it was significantly lower at 3.0% (4/135,
95% CI, 1.2%, 7.4%) (Figure 1) (p < 0.001 using McNe-
mar's test).
Imaging cost implications of screening strategies for 
pheochromocytoma
In the decision analysis, biochemical testing by measure-
ment of fractionated plasma metanephrines (traditional
versus age-adjusted interpretation) was followed by CT
imaging for all positive biochemical tests and if CT imag-
ing was negative, then MIBG (I-123 or I-131) would be
performed (Figure 2). For the purpose of the economic
evaluation, in all three screening strategies, a 0.5% preva-
lence of pheochromocytoma was assumed in a target
hypertensive population, so 500 patients with pheochro-
mocytoma would be expected in a sample of 100,000
hypertensive subjects (Figure 2). Mayo Clinic Rochester
charges for diagnostic studies were used: CT scan of the
abdomen (with and without contrast) $1460, I-123 MIBG
scan (with and without spect) $1875.
If 100,000 subjects with hypertension would be screened
using algorithm "A" (beginning with biochemical testing
by measurement of fractionated plasma metanephrines,
traditional interpretation), 499/500 patients with pheo-
chromocytoma (overall sensitivity 99.8%) would be
expected to be detected (1 patient expected to have false
negative CT and MIBG imaging); furthermore 94,510/
99,500 of subjects without pheochromocytoma would be
reassured with a negative diagnosis (overall specificity
95.0%). In algorithm "A", 16,718 individuals would
undergo CT scanning and 11,363 individuals would
undergo I-123 or I-131 MIBG imaging. The total cost of
imaging for algorithm "A" would be estimated to be 45.7
million dollars.
If algorithm "B" (biochemical testing using the age-
adjusted metanephrine score) would be used in 100,000
subjects with hypertension, 499/500 patients with pheo-
chromocytoma (99.8%) would be expected to be detected
and 98592/99,500 individuals without pheochromocy-
toma would be reassured with a negative test result (over-
all specificity of 99.1%). In algorithm "B", 3,485
individuals would undergo CT scanning and 2,100 indi-
viduals would undergo I-123 or I-131 MIBG imaging. The
cost of imaging for algorithm "B" would be approximately
9.0 million dollars. Thus, use of the age-adjusted plasma
metanephrine score for biochemical testing for sporadic
pheochromocytoma in a hypothetical population of
100,000 tertiary care hypertensive patients could result in
a cost savings of 36.7 million dollars with equal detection
of pheochromocytoma cases, relative to using the same
biochemical testing but interpreting fractionated plasma
metanephrine measurements in a traditional fashion.
Table 1: Clinical characteristics of subjects without pheochromocytoma from the derivation set
Clinical characteristic True negative Measurements 
of fractionated plasma 
metanephrines (n = 264)
False positive Measurements 
of fractionated plasma 
metanephrines (n = 46)
Significance testing results
Gender (females/n) 142/264 26/46 P = 0.73 (χ2 = 0.12, df = 1)
Age (mean, SD years) 50.7 (15.03) 57.3 (14.6) P = 0.007 (t = 2.81, df = 63)
Systolic blood pressure (mean, 
SD mmHg)
147 (26) (n = 260) 153 (32) P = 0.24 (t = 1.19, df = 56)
Diastolic blood pressure (mean, 
SD mmHg)
87 (12) (n = 260) 89 (15) P = 0.39 (t = 0.87, df = 57)
Number of antihypertensive 
agents currently used (mean, SD)
1.4 (1.5) 1.6 (1.3) P = 0.28 (t = 1.09, df = 70)
Known diagnosis of obstructive 
sleep apnea
15/264 4/46 P = 0.43 (χ2 = 0.62, df = 1)BMC Endocrine Disorders 2005, 5:1 http://www.biomedcentral.com/1472-6823/5/1
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Discussion
We agree with observation by Eisenhofer and colleagues
that when it comes to measurement of fractionated
plasma metanephrines for exclusion of pheochromocy-
toma, "false-positive results remain a problem" [12], par-
ticularly when attempting to exclude sporadic disease.
Originally, it was the hope was that measurement of frac-
tionated plasma metanephrines could result in cost sav-
ings because of avoidance of multiple biochemical tests
[19]. However, investigators from the National Institute
of Health have recommended that clonidine-suppression
tests need to be done in order to distinguish true positives
from false positives [12]. An alternative to clonidine-sup-
pression testing may be measurement of 24-hour urinary
metanephrines and catecholamines in patients with mild
to moderate elevations of the normetanephrine fraction
(for normetanephrine values approximately one to two
times the upper limit of the normal range) [13]. In our
study, we have provided a unique alternative approach for
improving specificity of interpretation of measurements
of fractionated plasma metanephrines. By adjusting the
metanephrine score for age, we have shown that it may be
possible to improve specificity of interpretation of
fractionated plasma metanephrines, with no loss of sensi-
Percentage of false positive test results (and 95% confidence interval) at 100% sensitivity in using a traditional interpretation of  fractionated plasma metanephrine measurements or an age-adjusted metanephrine score Figure 1
Percentage of false positive test results (and 95% confidence interval) at 100% sensitivity in using a traditional 
interpretation of fractionated plasma metanephrine measurements or an age-adjusted metanephrine score. 
Legend – Pmet(s), fractionated plasma metanephrine measurements; traditional fractionated plasma metanephrine measure-
ments are considered positive if the metanephrine fraction is greater than or equal to 0.5 nmol/L or the normetanephrine frac-
tion is greater than or equal to 0.9 nmol/L; an age-adjusted metanephrine score is positive if it is greater than -1.4752. The 
difference between false positive rates is statistically significant with p < 0.001 using McNemar's test.BMC Endocrine Disorders 2005, 5:1 http://www.biomedcentral.com/1472-6823/5/1
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tivity in detection of sporadic pheochromocytoma, and
potential savings in imaging expenditures.
Of note, the sensitivity of the age-adjusted metanephrine
score was superior in the validation set (100%) to that
observed in the original dataset from which it was derived
(91%). An explanation for this finding may be that the
validation set included only people who were at risk for
sporadic pheochromocytoma (in other words, non-genet-
ically predisposed individuals), whereas genetically pre-
disposed individuals were included in the original
derivation dataset. We have previously observed that frac-
tionated plasma metanephrine measurements may be
normal in genetically-predisposed individuals with small
pheochromocytomas [11]. Moreover, the physiologic
cause for the observed relationship of normetanephrine
measurements with age is unclear. Of note, Raber et al
have noted exaggerated increases in plasma normetane-
phrine after exercise in hypertensive individuals with type
2 diabetes, compared to normotensive individuals with or
without diabetes [20]. Furthermore, Raber et al have sug-
gested that the excessive response of plasma normetane-
phrine to exercise may serve as a marker of exaggerated
sympathoadrenal function in hypertensive type 2 diabet-
ics [20]. Fractionated plasma metanephrine measure-
ments were performed only at rest in our study and we did
not examine any potential relationship with diabetes.
Systolic and diastolic blood pressures were not signifi-
cantly different between individuals with false positive
fractionated metanephrine measurements and those with
Decision analysis: Testing algorithm for pheochromocytoma in 100,000 hypothetical hypertensive subjects (including 500 indi- viduals with pheochromocytoma) Figure 2
Decision analysis: Testing algorithm for pheochromocytoma in 100,000 hypothetical hypertensive subjects (including 500 indi-
viduals with pheochromocytoma)BMC Endocrine Disorders 2005, 5:1 http://www.biomedcentral.com/1472-6823/5/1
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true negative measurements in the derivation set in our
study.
Our study is subject to several limitations. Firstly, limited
clinical data on each studied individual were collected so
variables that could be of interest such as: body mass
index, creatinine-clearance, and rates of diabetes mellitus
were not recorded. Furthermore, without autopsy confir-
mation, one cannot be absolutely certain that individuals
labelled as not having a pheochromocytoma did not have
an occult paraganglioma or pheochromocytoma. How-
ever, we believe that reasonable clinical criteria were used
in excluding pheochromocytoma in our study. Another
limitation is that we used an assay for measurement of
fractionated plasma metanephrines that may be have
been subject to interference with acetaminophen [8],
whereas other assays, such as the one described by Roden
et al, could have been preferable due to lack of acetami-
nophen interference [21]. The cut-off that we chose for
positivity of the age-adjusted metanephrine score was also
arbitrary and use of a lower cut-off could have resulted in
improved sensitivity, albeit with likely some expense of
specificity. Finally, our findings have not been validated
outside a single institution.
Is calculation of an age-adjusted metanephrine score prac-
tical for use in daily clinical practice? In this day of palm
pilots and desktop computers, we believe that it may be
feasible for clinicians to enter the formula for age-adjust-
ment into standard desktop spreadsheet software (such as
Excel, Microsoft) and perform such adjustments in the
clinic. Alternatively, laboratories can provide age adjusted
values to physicians when reporting test results. Thus, we
do believe that calculation of an age-adjusted score is fea-
sible to assist physicians in interpretation of fractionated
plasma metanephrine measurements. Indeed, such calcu-
lations may be less cumbersome and may generate fewer
healthcare expenditures than alternative procedures such
as supplemental clonidine-suppression testing or collec-
tion of 24-hour urinary measures.
Our observations should, however, be validated in
another population outside of Mayo Clinic. Of particular
note, our findings are applicable only to the screening of
pheochromocytoma in low risk subjects who do not have
known genetic predisposition to disease. In high risk,
genetically predisposed individuals, mild elevations of
normetanephrine or metanephrine measurements may be
clinically significant and should prompt imaging.
Conclusion
An adjustment for age in interpretation of results of frac-
tionated plasma metanephrine measurements may signif-
icantly improve the high false positive rate seen with this
test when aiming to exclude sporadic pheochromocy-
toma. This improvement in specificity may result in sav-
ings in expenditures related to confirmatory imaging.
Additional research is needed to investigate the generaliz-
ability of these findings in other clinical centres.
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